S&P 500   3,971.35 (+0.01%)
DOW   32,375.05 (+0.43%)
QQQ   309.27 (-0.52%)
AAPL   159.21 (-0.65%)
MSFT   277.22 (-1.19%)
META   202.87 (-1.52%)
GOOGL   102.75 (-2.55%)
AMZN   97.54 (-0.60%)
TSLA   194.71 (+2.26%)
NVDA   266.33 (-0.55%)
NIO   8.88 (-2.09%)
BABA   85.58 (-1.52%)
AMD   96.22 (-1.77%)
T   18.88 (+1.45%)
F   11.50 (-0.09%)
MU   59.55 (-2.63%)
CGC   1.88 (-1.32%)
GE   93.08 (+1.87%)
DIS   94.63 (+0.58%)
AMC   4.32 (-3.36%)
PYPL   73.77 (-0.15%)
PFE   40.34 (-0.12%)
NFLX   329.75 (+0.41%)
S&P 500   3,971.35 (+0.01%)
DOW   32,375.05 (+0.43%)
QQQ   309.27 (-0.52%)
AAPL   159.21 (-0.65%)
MSFT   277.22 (-1.19%)
META   202.87 (-1.52%)
GOOGL   102.75 (-2.55%)
AMZN   97.54 (-0.60%)
TSLA   194.71 (+2.26%)
NVDA   266.33 (-0.55%)
NIO   8.88 (-2.09%)
BABA   85.58 (-1.52%)
AMD   96.22 (-1.77%)
T   18.88 (+1.45%)
F   11.50 (-0.09%)
MU   59.55 (-2.63%)
CGC   1.88 (-1.32%)
GE   93.08 (+1.87%)
DIS   94.63 (+0.58%)
AMC   4.32 (-3.36%)
PYPL   73.77 (-0.15%)
PFE   40.34 (-0.12%)
NFLX   329.75 (+0.41%)
S&P 500   3,971.35 (+0.01%)
DOW   32,375.05 (+0.43%)
QQQ   309.27 (-0.52%)
AAPL   159.21 (-0.65%)
MSFT   277.22 (-1.19%)
META   202.87 (-1.52%)
GOOGL   102.75 (-2.55%)
AMZN   97.54 (-0.60%)
TSLA   194.71 (+2.26%)
NVDA   266.33 (-0.55%)
NIO   8.88 (-2.09%)
BABA   85.58 (-1.52%)
AMD   96.22 (-1.77%)
T   18.88 (+1.45%)
F   11.50 (-0.09%)
MU   59.55 (-2.63%)
CGC   1.88 (-1.32%)
GE   93.08 (+1.87%)
DIS   94.63 (+0.58%)
AMC   4.32 (-3.36%)
PYPL   73.77 (-0.15%)
PFE   40.34 (-0.12%)
NFLX   329.75 (+0.41%)
S&P 500   3,971.35 (+0.01%)
DOW   32,375.05 (+0.43%)
QQQ   309.27 (-0.52%)
AAPL   159.21 (-0.65%)
MSFT   277.22 (-1.19%)
META   202.87 (-1.52%)
GOOGL   102.75 (-2.55%)
AMZN   97.54 (-0.60%)
TSLA   194.71 (+2.26%)
NVDA   266.33 (-0.55%)
NIO   8.88 (-2.09%)
BABA   85.58 (-1.52%)
AMD   96.22 (-1.77%)
T   18.88 (+1.45%)
F   11.50 (-0.09%)
MU   59.55 (-2.63%)
CGC   1.88 (-1.32%)
GE   93.08 (+1.87%)
DIS   94.63 (+0.58%)
AMC   4.32 (-3.36%)
PYPL   73.77 (-0.15%)
PFE   40.34 (-0.12%)
NFLX   329.75 (+0.41%)
NASDAQ:VKTX

Viking Therapeutics - VKTX Stock Forecast, Price & News

$9.23
+0.38 (+4.29%)
(As of 03/27/2023 11:40 AM ET)
Add
Compare
Today's Range
$8.86
$9.54
50-Day Range
$8.40
$11.83
52-Week Range
$2.02
$11.98
Volume
866,252 shs
Average Volume
2.14 million shs
Market Capitalization
$723.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50

Viking Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
92.1% Upside
$17.50 Price Target
Short Interest
Bearish
7.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
1.69mentions of Viking Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.96) to ($1.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

538th out of 995 stocks

Pharmaceutical Preparations Industry

248th out of 482 stocks


VKTX stock logo

About Viking Therapeutics (NASDAQ:VKTX) Stock

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Stock News Headlines

Is Viking Therapeutics a Smart Buy on the Dip?
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Viking Therapeutics: Some Caution Warranted
4 Analysts Have This to Say About Viking Therapeutics
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
2 Surging Healthcare Stocks That Are Still Worth Buying
Viking Therapeutics's Earnings: A Preview
VKTX.OQ - | Stock Price & Latest News | Reuters
VKTX Viking Therapeutics, Inc.
SVB Securities Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Recap: Viking Therapeutics Q3 Earnings
See More Headlines
Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Company Calendar

Last Earnings
2/08/2023
Today
3/27/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VKTX
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.50
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+87.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-68,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.89 per share

Miscellaneous

Free Float
74,106,000
Market Cap
$734.01 million
Optionable
Optionable
Beta
0.77

Key Executives

  • Brian Lian
    President, Chief Executive Officer & Director
  • Marianne Mancini
    Chief Operating Officer
  • Gregory S. Zante
    Chief Financial Officer
  • Michael Morneau
    Vice President-Finance & Administration













VKTX Stock - Frequently Asked Questions

Should I buy or sell Viking Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings
or view top-rated stocks.

What is Viking Therapeutics' stock price forecast for 2023?

4 brokers have issued 12 month target prices for Viking Therapeutics' shares. Their VKTX share price forecasts range from $12.00 to $22.00. On average, they anticipate the company's stock price to reach $17.50 in the next year. This suggests a possible upside of 87.0% from the stock's current price.
View analysts price targets for VKTX
or view top-rated stocks among Wall Street analysts.

How have VKTX shares performed in 2023?

Viking Therapeutics' stock was trading at $9.40 at the beginning of the year. Since then, VKTX shares have decreased by 0.4% and is now trading at $9.36.
View the best growth stocks for 2023 here
.

When is Viking Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our VKTX earnings forecast
.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings results on Wednesday, February, 8th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.03.

What ETFs hold Viking Therapeutics' stock?
What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Boxer Capital LLC (1.96%), Two Sigma Investments LP (1.65%), Point72 Asset Management L.P. (1.44%), Renaissance Technologies LLC (1.24%), Dimensional Fund Advisors LP (1.11%) and Geode Capital Management LLC (0.85%). Insiders that own company stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of Viking Therapeutics?

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $9.36.

How much money does Viking Therapeutics make?

Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $734.01 million. The biotechnology company earns $-68,870,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com.

This page (NASDAQ:VKTX) was last updated on 3/27/2023 by MarketBeat.com Staff